Lipocine Inc. is a clinical-stage pharmaceutical company specializing in the development and commercialization of oral drug-delivery technologies for endocrine and metabolic disorders. The company’s proprietary lipid-based delivery platforms are designed to enhance the absorption and bioavailability of lipophilic compounds, with an initial focus on testosterone replacement therapy. Through these innovative formulations, Lipocine aims to offer patient-friendly alternatives to injectable or transdermal treatments.
The company’s lead asset, TLANDO, is an FDA-approved oral testosterone product for the treatment of male hypogonadism. TLANDO is designed to be taken twice daily and provides a predictable pharmacokinetic profile without the need for dose titration. In addition to its commercial efforts for TLANDO, Lipocine is advancing a pipeline of oral prodrug candidates, including LPCN 1144 for non-alcoholic steatohepatitis (NASH) and LPCN 1148, a testosterone formulation aimed at addressing bone health in men with osteoporosis.
Founded in 2003 and headquartered in Salt Lake City, Utah, Lipocine completed its initial public offering in 2013 and has since established strategic collaborations to support its commercialization and development objectives. The company holds a broad portfolio of patents covering its lipid-based delivery systems, and it continues to explore new indications and partnerships to expand the reach of its oral therapies.
Lipocine’s leadership team brings together seasoned professionals from the pharmaceutical and biotechnology sectors. Chief Executive Officer Ilya Yuffa, who joined the company’s board in 2019 and assumed the CEO role in 2021, is supported by a management team with expertise in regulatory affairs, clinical development, and commercial strategy. As Lipocine advances its oral drug-delivery platforms, it remains committed to addressing unmet medical needs and improving patient adherence through innovative dosage forms.
AI Generated. May Contain Errors.
Free LPCN Stock Alerts